Industry: Therapeutics for metastatic cancer
MetCure Therapeutics is discovering and developing new drugs to treat metastatic cancer.
The company has developed a prostate cancer cell line that exhibits the characteristics of malignant, chemo-resistant human cancer cells. Using its proprietary high-throughput screening platform, MetCure is testing and identifying compounds that serve as effective drugs against these lethal cells.
MetCure has identified LG1980 as one lead compound and outlined the mechanism LG1980 uses to attack prostate cancer cells. Other cancer stem cell inhibitors are also being explored.
Prostate cancer is the second-leading cause of deaths from cancer in U.S. males, and metastatic cancers represent most of those deaths. Current treatments for metastatic cancer often fail, making better therapeutics absolutely essential.
The global bone metastasis therapeutics market was valued at $2.4 billion in 2013 and is projected to reach $6.4 billion by 2017.
Company website: MetCure Therapeutics